Article Information
History
- October 19, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Garyfallia Poulakou1,
- Pierre-Joseph Royer2,
- Nikolai Evgeniev3,
- Gwénaëlle Evanno2,
- Françoise Shneiker2,*,
- Bernard Vanhove2,
- Odile Duvaux2,
- Stéphane Marot4 and
- Vincent Calvez4
- 13rd Department of Internal Medicine, Medical School, Sotiria General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
- 2Xenothera, Nantes, France
- 3Complex Oncology Center, Department of Medical oncology, Russe, Bulgaria
- 4Sorbonne Université, INSERM 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
- ↵*Corresponding author; email: francoise.shneiker{at}xenothera.com
Posted October 19, 2023.
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants
